CMT

Core Molding Technologies Reports Fiscal 2023 Third Quarter Results

Retrieved on: 
Tuesday, November 7, 2023

COLUMBUS, Ohio, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2023.

Key Points: 
  • COLUMBUS, Ohio, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2023.
  • The term debt-to-trailing twelve months Adjusted EBITDA1 was less than one times Adjusted EBITDA1 at the end of the fiscal third quarter.
  • The Company will conduct a conference call today at 10:00 a.m. Eastern Time to discuss financial and operating results for the quarter ended September 30, 2023.
  • To access the call live by phone, dial (844) 881-0134 and ask for the Core Molding Technologies call at least 10 minutes prior to the start time.

Former NBC's The Voice Contestant Joey Green Takes A Journey With The Release Of New Album "Heart Lessons" and Drops "The Worst" Music Video

Retrieved on: 
Tuesday, November 7, 2023

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- Joey Green, the talented Texan who captured hearts across the nation during his run on NBC's The Voice, has unveiled his latest album, "Heart Lessons," available today on all major digital music platforms. This album seamlessly blends Joey's signature mix of rock 'n' roll, soulful country, and a touch of 90s alternative. In celebration of this exciting album release, Joey Green has also launched the music video for his track "The Worst" which can be viewed online here.

Key Points: 
  • In celebration of this exciting album release, Joey Green has also launched the music video for his track "The Worst," This playful video humorously portrays Joey navigating awkward situations as he grapples with the challenges of a modern millennial world.
  • This album seamlessly blends Joey's signature mix of rock 'n' roll, soulful country, and a touch of 90s alternative.
  • In celebration of this exciting album release, Joey Green has also launched the music video for his track "The Worst" which can be viewed online here .
  • For more information about Joey Green, his music, or to request an interview, please visit his official website at www.listentojoeygreen.com .

Core Molding Technologies Appoints New Board Member

Retrieved on: 
Thursday, November 2, 2023

COLUMBUS, Ohio, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), announced today that Salvador Miñarro has been appointed to its Board of Directors.

Key Points: 
  • COLUMBUS, Ohio, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), announced today that Salvador Miñarro has been appointed to its Board of Directors.
  • Mr. Miñarro is the Chief Executive Officer of Darnel Group, a global leader in the production of high-quality, food-grade sustainable packaging solutions and a pioneer in post-consumer recycled material.
  • “We are pleased to have Sal join the Board and look forward to his contributions to the Company.
  • We are excited to have Sal as part of the Core team,” Cellitti continued.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

DSS Inc. Issues Letter to Shareholders

Retrieved on: 
Thursday, October 12, 2023

ROCHESTER, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that it has issued a Letter to Shareholders.

Key Points: 
  • ROCHESTER, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that it has issued a Letter to Shareholders.
  • The structure of this spinoff is designed for DSS to maintain the consolidation of IBIO's financials, ensuring our shareholders receive the benefits of IBIO’s success on a go forward basis.
  • Our commitment to reinforcing our leadership dynamics is evident in the recent enhancement of the management team at DSS Wealth Management, Inc.
  • Post the Impact Biomedical IPO, we eagerly look forward to introducing our shareholders to our subsequent spinoffs or similar liquidity events.

Core Molding Technologies Announces Timing of Third Quarter Fiscal 2023 Results

Retrieved on: 
Thursday, October 12, 2023

COLUMBUS, Ohio, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America, today announces that it will release its third quarter fiscal 2023 results on Tuesday, November 7, 2023, before the market opens.

Key Points: 
  • COLUMBUS, Ohio, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America, today announces that it will release its third quarter fiscal 2023 results on Tuesday, November 7, 2023, before the market opens.
  • In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the internet the same day at 10:00am Eastern.
  • Dial 1-844-881-0134 at least 10 minutes before the call and ask to join the Core Molding Technologies call.
  • Connect to the webcast via the Events and Presentations page of Core Molding’s Investor Relations website at www.coremt.com/investor-relations/events-presentations/ .

Usage Based Insurance Market worth $80.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 13, 2023

Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.

Key Points: 
  • Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.
  • North America has UBI's top key players: Allstate Insurance Company, Farmers Insurance, Nationwide Mutual Insurance Company, Progressive Casualty Insurance Company, State Farm Mutual Automobile Insurance Company, etc.
  • The usage-based insurance companies in North America, are UnipolSai Assicurazioni S.p.A (Italy), Progressive Casualty Insurance Company (US), Allstate Insurance Company (US), State Farm Automobile Mutual Insurance Company (US), and Liberty Mutual Insurance Company (US).
  • In July 2021, Unipol's Linear Assicurazioni and Cambridge Mobile Telematics (CMT) launched Italy's first try-before-you-buy auto insurance program.

Usage Based Insurance Market worth $80.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, October 13, 2023

Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.

Key Points: 
  • Battery electric vehicles (BEVs) are equipped with various sensors that generate data about vehicle usage, such as speed, mileage, braking patterns, and battery usage.
  • North America has UBI's top key players: Allstate Insurance Company, Farmers Insurance, Nationwide Mutual Insurance Company, Progressive Casualty Insurance Company, State Farm Mutual Automobile Insurance Company, etc.
  • The usage-based insurance companies in North America, are UnipolSai Assicurazioni S.p.A (Italy), Progressive Casualty Insurance Company (US), Allstate Insurance Company (US), State Farm Automobile Mutual Insurance Company (US), and Liberty Mutual Insurance Company (US).
  • In July 2021, Unipol's Linear Assicurazioni and Cambridge Mobile Telematics (CMT) launched Italy's first try-before-you-buy auto insurance program.

Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials

Retrieved on: 
Thursday, September 28, 2023

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen) and Elpida Therapeutics (Elpida Tx) have partnered to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with SPG50 or CMT4J.

Key Points: 
  • SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen) and Elpida Therapeutics (Elpida Tx) have partnered to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with SPG50 or CMT4J.
  • It is anticipated that these trials will take place at various sites in North America and Europe and will explore potential safety and efficacy of the new treatments to be manufactured, as well as potential quality of life improvements.
  • The same CMT4J genotype can present symptoms ranging from mild clinical signs to severe disability.2
    The partnership between Viralgen and Elpida Tx is expected to enable the efficient manufacture of the adeno-associated vector serotype 9 (AAV9) based therapies for use in Elpida Tx's anticipated multi-site clinical trials.
  • We feel so grateful and honored to be working with such an incredible partner."

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

Retrieved on: 
Thursday, September 28, 2023

Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.
  • Drugs that inhibit the molecular target HDAC6 are a novel class of therapeutics that are able to functionally enhance the axonal transport of nutrients, growth factors and neurotransmitters in neurons.
  • Encouraged by scientific studies that have shown efficacy in rodent models of neurodegenerative disorders, PurMinds NeuroPharma anticipates the successful development of an HDAC6 inhibitor for Charcot-Marie Tooth Disease (CMT) - a progressive neurodegenerative disorder, which causes disabling deficits in nerve function affecting 1 in 2500 people with no current cure.
  • "HDAC6 inhibition represents an innovative therapeutic target to address a range of neurological conditions currently without a cure.